AI Drug Startup Insilico Weighs Hong Kong IPO After Funding (2)

Insilico Medicine Inc. is considering an initial public offering after securing funding at a valuation of more than $1 billion, reflecting growing interest in the potential use of AI to discover ground-breaking new drugs.

US-based Insilico, which has extensive operations in China, secured $110 million in a financing round led by Value Partners Group. Existing backers include Warburg Pincus,US biotech investor OrbiMed Advisors Llc and the venture arm of Eli Lilly & Co., the company said in a statement.

Investor interest in generative AI startups has soared around the region since the emergence of China’s DeepSeek ...